Related Experiment Video

Updated: May 24, 2026

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

Unveiling novel drug targets for atherosclerosis: A Mendelian randomization analysis

Wenzhi Du1,2, Dazheng Li2, Na Li3

  • 1Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.

Medicine
|May 23, 2026
PubMed

Insights

This study used Mendelian randomization to identify new drug targets for atherosclerosis, a major cause of heart disease. Lipoprotein (a) and proprotein convertase subtilisin/kexin type 9 show promise for future treatments.

Area of Science:

  • Cardiovascular Science
  • Genetics
  • Pharmacology

Background:

  • Atherosclerosis is a primary driver of cardiovascular diseases.
  • Novel therapeutic targets are crucial for managing atherosclerosis.
  • Existing treatments require complementary strategies.

Purpose of the Study:

  • To identify potential drug targets for atherosclerosis using Mendelian randomization.
  • To investigate the causal relationship between circulating proteins and atherosclerosis risk.
  • To validate identified targets through robust statistical methods.

Main Methods:

  • Mendelian randomization analysis.
  • Genome-wide association study (GWAS) data.
  • Protein quantitative trait loci (pQTL) data.
  • Multiple statistical validation approaches.

Main Results:

  • Genetically identified causal links between specific circulating proteins and atherosclerosis risk.
  • Validated the association of several proteins with atherosclerosis.
  • Highlighted lipoprotein (a) and proprotein convertase subtilisin/kexin type 9 as promising targets.

Conclusions:

  • The study identified novel, genetically supported therapeutic targets for atherosclerosis.
  • Lipoprotein (a) and proprotein convertase subtilisin/kexin type 9 warrant further clinical investigation.
  • Findings contribute to the development of advanced cardiovascular disease therapies.

Keywords:
atherosclerosisdrug targetsmendelian randomization

More Related Videos

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans08:21

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans

Published on: July 21, 2023

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...